PDE7B

Summary

PDE7B (phosphodiesterase 7B, HGNC:8792) is a protein-coding gene on chromosome 6q23.3, encoding 3’,5’-cyclic-AMP phosphodiesterase 7B (Q9NP56). Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.

The 3’,5’-cyclic nucleotides cAMP and cGMP function as second messengers in a wide variety of signal transduction pathways. 3’,5’-cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cGMP to the corresponding 5’-monophosphates and provide a mechanism to downregulate cAMP and cGMP signaling. This gene encodes a cAMP-specific phosphodiesterase, a member of the cyclic nucleotide phosphodiesterase family.

Source: NCBI Gene 27115 — RefSeq curated summary.

At a glance

• GWAS associations: 28
• Clinical variants (ClinVar): 64 total
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_018945

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8792
Approved symbol	PDE7B
Name	phosphodiesterase 7B
Location	6q23.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000171408
Ensembl biotype	protein_coding
OMIM	604645
Entrez	27115

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000308191, ENST00000446774, ENST00000615259

RefSeq mRNA: 1 — MANE Select: NM_018945 NM_018945

CCDS: CCDS5175

Canonical transcript exons

ENST00000308191 — 13 exons

Exon	Start	End
ENSE00001124631	136187036	136187116
ENSE00001124639	136181227	136181323
ENSE00001124644	136178997	136179141
ENSE00001124649	136173797	136173888
ENSE00001124656	136155627	136155758
ENSE00001124667	136151160	136151255
ENSE00001124674	136149087	136149150
ENSE00001124680	136147351	136147502
ENSE00001124687	136108731	136108814
ENSE00001365942	135947464	135947524
ENSE00001445635	135851701	135852019
ENSE00001904471	136191614	136195574
ENSE00002097427	136154075	136154175

Expression profiles

Bgee: expression breadth ubiquitous, 233 present calls, max score 88.41.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.8292 / max 371.0441, expressed in 1132 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
69938	3.7639	804
69939	3.6656	818
69947	1.3438	502
69937	0.7412	354
69948	0.5943	345
69935	0.5656	285
69949	0.2842	144
69943	0.1956	109
69936	0.1558	81
69946	0.1477	88

Top tissues by expression

276 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
germinal epithelium of ovary	UBERON:0001304	88.41	gold quality
calcaneal tendon	UBERON:0003701	86.73	gold quality
lateral globus pallidus	UBERON:0002476	86.57	gold quality
nucleus accumbens	UBERON:0001882	85.54	gold quality
middle temporal gyrus	UBERON:0002771	85.30	gold quality
buccal mucosa cell	CL:0002336	85.12	silver quality
tibia	UBERON:0000979	85.06	gold quality
caudate nucleus	UBERON:0001873	84.22	gold quality
putamen	UBERON:0001874	83.88	gold quality
endothelial cell	CL:0000115	83.83	silver quality
body of tongue	UBERON:0011876	82.95	gold quality
saphenous vein	UBERON:0007318	82.94	gold quality
vena cava	UBERON:0004087	82.88	gold quality
occipital lobe	UBERON:0002021	82.78	gold quality
primary visual cortex	UBERON:0002436	82.77	gold quality
ventral tegmental area	UBERON:0002691	82.62	gold quality
seminal vesicle	UBERON:0000998	82.46	gold quality
subthalamic nucleus	UBERON:0001906	82.23	gold quality
Brodmann (1909) area 23	UBERON:0013554	82.22	gold quality
left ovary	UBERON:0002119	82.21	gold quality
lateral nuclear group of thalamus	UBERON:0002736	82.13	gold quality
cardia of stomach	UBERON:0001162	82.05	gold quality
stromal cell of endometrium	CL:0002255	81.91	gold quality
parietal pleura	UBERON:0002400	81.77	gold quality
superior surface of tongue	UBERON:0007371	81.49	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	81.42	gold quality
substantia nigra pars reticulata	UBERON:0001966	81.28	gold quality
ovary	UBERON:0000992	81.12	gold quality
substantia nigra pars compacta	UBERON:0001965	81.09	gold quality
dorsal plus ventral thalamus	UBERON:0001897	81.00	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-30	yes	509.89
E-CURD-119	yes	17.12
E-HCAD-35	yes	8.81
E-ANND-3	yes	5.74

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA3

miRNA regulators (miRDB)

217 targeting PDE7B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6740-5P	100.00	65.64	932
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-3617-3P	99.98	67.86	918

Literature-anchored findings (GeneRIF, showing 12)

• higher levels than in normal B-cell of PDE7B are found in chronic lymphocytic leukemia (PMID:19033455)
• As a first exploitation of this unique cohort, we identify three novel candidate dyslexia genes, ZNF280D and TCF12 at 15q21, and PDE7B at 6q23.3, by molecular mapping of the familial translocation with the 15q21 breakpoint. (PMID:20798984)
• High PDE7B is associated with chronic lymphocytic leukemia. (PMID:21120911)
• PDE7B mRNA expression is obviously higher in mantle cell lymphoma patients compared with normal controls and significantly correlates with unfavorable cytogenetic characteristics. (PMID:21362230)
• Genetic variation in the phosphodiesterase 7B is associated with bioavailability of testosterone enanthate. (PMID:21383644)
• The low frequency of this 5’ untranslated region variant indicates that it does not explain the higher PDE7B expression in patients with chronic lymphocytic leukemia (CLL) but it has the potential to influence other settings that involve a role for PDE7B. (PMID:21796143)
• higher expression of PDE7B might be a novel unfavorable prognostic indicator in MCL, which possess important clinical significance. (PMID:23453122)
• PDE7B polymorphisms were not associated with schizophrenia risk. (PMID:27092952)
• both low miR-200c and high PDE7B expression were correlated with poor survival of breast cancer patients. Our study supports a critical role of miR-200c/PDE7B relationship in triple-negative breast cancer tumorigenesis. (PMID:30209363)
• We have identified three novel loci (PDE7B, UBL3, and a new independent marker in CDKN2B-AS1) associated with BRCAX, and replicated previously reported SNPs (24 of 92) and moderate/high-penetrance (seven of 23) genes for Korean BRCAX. For the novel candidate loci, evidence supported their roles in regulatory function (PMID:30323354)
• The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia. (PMID:31740742)
• Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K/AKT signaling pathway. (PMID:38778317)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
mus_musculus	Pde7b	ENSMUSG00000019990
rattus_norvegicus	Pde7b	ENSRNOG00000013436
drosophila_melanogaster	Pde11	FBGN0085370
drosophila_melanogaster	Pde8	FBGN0266377
caenorhabditis_elegans		WBGENE00008443
caenorhabditis_elegans	pde-6	WBGENE00022389

Paralogs (20): PDE4A (ENSG00000065989), PDE8A (ENSG00000073417), PDE6C (ENSG00000095464), PDE4C (ENSG00000105650), PDE10A (ENSG00000112541), PDE8B (ENSG00000113231), PDE4D (ENSG00000113448), PDE1A (ENSG00000115252), PDE1B (ENSG00000123360), PDE11A (ENSG00000128655), PDE6A (ENSG00000132915), PDE6B (ENSG00000133256), PDE5A (ENSG00000138735), PDE3B (ENSG00000152270), PDE1C (ENSG00000154678), PDE9A (ENSG00000160191), PDE3A (ENSG00000172572), PDE4B (ENSG00000184588), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268)

Protein

Protein identifiers

3’,5’-cyclic-AMP phosphodiesterase 7B — Q9NP56 (reviewed: Q9NP56)

Alternative names: cAMP-specific phosphodiesterase 7B

All UniProt accessions (3): A1E5M1, Q9NP56, H0Y689

UniProt curated annotations — full annotation on UniProt →

Function. Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in the control of cAMP-mediated neural activity and cAMP metabolism in the brain.

Tissue specificity. Highly expressed in brain. Also expressed in heart, liver, skeletal muscle and pancreas.

Activity regulation. Inhibited by dipyridamole, IBMX and SCH 51866. Insensitive to zaprinast, rolipram, and milrinone.

Cofactor. Binds 2 divalent metal cations per subunit. Site 1 may preferentially bind zinc ions, while site 2 has a preference for magnesium and/or manganese ions.

Domain organisation. Composed of a C-terminal catalytic domain containing two putative divalent metal sites and an N-terminal regulatory domain.

Pathway. Purine metabolism; 3’,5’-cyclic AMP degradation; AMP from 3’,5’-cyclic AMP: step 1/1.

Similarity. Belongs to the cyclic nucleotide phosphodiesterase family. PDE7 subfamily.

RefSeq proteins (1): NP_061818* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002073	PDEase_catalytic_dom	Domain
IPR003607	HD/PDEase_dom	Domain
IPR023088	PDEase	Family
IPR023174	PDEase_CS	Conserved_site
IPR036971	PDEase_catalytic_dom_sf	Homologous_superfamily

Pfam: PF00233

Enzyme classification (BRENDA):

• EC 3.1.4.53 — 3’,5’-cyclic-AMP phosphodiesterase (BRENDA: 28 organisms, 62 substrates, 307 inhibitors, 60 Km, 12 kcat entries)

Substrate kinetics (BRENDA)

6 substrates with measured Km, best-characterized 6. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ADENOSINE 3’,5’-CYCLIC PHOSPHATE	—	34
3’,5’-CAMP	0.0003–0.5	13
CAMP	0.0001–0.191	9
CGMP	0.24–0.427	2
3’,5’-CGMP	1.6	1
GUANOSINE 3’,5’-CYCLIC PHOSPHATE	0.124	1

Catalyzed reactions (Rhea), 1 shown:

• 3’,5’-cyclic AMP + H2O = AMP + H(+) (RHEA:25277)

UniProt features (11 total): binding site 5, chain 1, domain 1, modified residue 1, region of interest 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NP56-F1	79.84	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 173 (proton donor)

Ligand- & substrate-binding residues (5): 177; 213; 214; 214; 323

Post-translational modifications (1): 426

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-418555	G alpha (s) signalling events

MSigDB gene sets: 206 (showing top): TAATAAT_MIR126, AAGCCAT_MIR135A_MIR135B, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, TATTATA_MIR374, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_CYCLIC_NUCLEOTIDE_METABOLIC_PROCESS, CACCAGC_MIR138, GOBP_CYCLIC_NUCLEOTIDE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_CELL_CELL_SIGNALING, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, RIGGI_EWING_SARCOMA_PROGENITOR_DN, GOBP_ORGANOPHOSPHATE_CATABOLIC_PROCESS, GOBP_SYNAPTIC_SIGNALING

GO Biological Process (4): cAMP catabolic process (GO:0006198), signal transduction (GO:0007165), chemical synaptic transmission (GO:0007268), negative regulation of cAMP/PKA signal transduction (GO:0141162)

GO Molecular Function (7): 3’,5’-cyclic-AMP phosphodiesterase activity (GO:0004115), metal ion binding (GO:0046872), 3’,5’-cyclic-GMP phosphodiesterase activity (GO:0047555), cyclic-nucleotide phosphodiesterase activity (GO:0004112), 3’,5’-cyclic-nucleotide phosphodiesterase activity (GO:0004114), phosphoric diester hydrolase activity (GO:0008081), hydrolase activity (GO:0016787)

GO Cellular Component (2): cytosol (GO:0005829), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
GPCR downstream signalling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
3’,5’-cyclic-nucleotide phosphodiesterase activity	2
purine ribonucleotide catabolic process	1
cyclic nucleotide catabolic process	1
cAMP metabolic process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
anterograde trans-synaptic signaling	1
cAMP/PKA signal transduction	1
regulation of cAMP/PKA signal transduction	1
negative regulation of intracellular signal transduction	1
cation binding	1
phosphoric diester hydrolase activity	1
cyclic-nucleotide phosphodiesterase activity	1
phosphoric ester hydrolase activity	1
catalytic activity	1
cytoplasm	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

876 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PDE7B	ALDH7A1	P49419	874
PDE7B	EXOC3L2	Q2M3D2	678
PDE7B	GUCY1B1	Q02153	486
PDE7B	ADCY7	P51828	484
PDE7B	AHI1	Q8N157	482
PDE7B	RAPGEF4	Q8WZA2	474
PDE7B	ADCY8	P40145	462
PDE7B	ALDH8A1	Q9H2A2	453
PDE7B	MAP3K5	Q99683	448
PDE7B	SEPTIN9	Q9UHD8	427
PDE7B	HBS1L	Q9Y450	419
PDE7B	AK8	Q96MA6	417
PDE7B	PDE6D	O43924	412
PDE7B	SLC12A4	Q9UP95	410
PDE7B	AKAP7	O43687	406

IntAct

3 interactions, top by confidence:

A	B	Type	Score
SRPK2	PDE7B	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
PDE7B	YWHAQ	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): ZNHIT6 (Affinity Capture-MS), YWHAQ (Affinity Capture-MS), HBB (Affinity Capture-MS), YWHAB (Affinity Capture-MS), RUFY3 (Affinity Capture-MS), YWHAZ (Affinity Capture-MS), YWHAG (Affinity Capture-MS), YWHAE (Affinity Capture-MS), PDE7B (Affinity Capture-MS), PDE7B (Affinity Capture-RNA), PDE7B (Biochemical Activity)

ESM2 similar proteins: A4IF87, A4IJ06, A6H611, A9JRL3, E1C3P4, G1SPE9, O08593, O15228, O54735, O88910, P14100, P54750, P70453, P98192, Q01061, Q01064, Q01065, Q01066, Q01992, Q07832, Q13946, Q14123, Q28156, Q2KIX2, Q2TBA3, Q32NJ2, Q32NM1, Q4R678, Q4U2V3, Q61481, Q62673, Q641K1, Q64395, Q69ZK0, Q6NTL4, Q6ZMV9, Q7Z6J4, Q8CA95, Q8TCU6, Q96EN8

Diamond homologs: A0A077YBL0, B0G0Y8, B3LVW5, B3P3K2, B4JXX2, B4K9L4, B4LVU6, B4NAL6, B4PSS5, B4QZU1, B7YZV4, E9Q4S1, H2QL32, O00408, O08593, O18696, O60658, O70628, O76083, O88502, O89084, O95263, P0C1Q2, P12252, P14099, P14100, P14270, P14644, P14646, P16586, P23439, P23440, P27815, P30645, P33726, P35913, P51160, P54748, P54750, P70453

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	51
Likely benign	1
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

2721 predictions. Top by Δscore:

Variant	Effect	Δscore
6:135947463:GA:G	acceptor_gain	1.0000
6:135947463:GAGGT:G	acceptor_gain	1.0000
6:136108815:G:GG	donor_gain	1.0000
6:136147501:GG:G	donor_gain	1.0000
6:136147502:GG:G	donor_gain	1.0000
6:136147503:G:GA	donor_loss	1.0000
6:136147503:G:GG	donor_gain	1.0000
6:136147504:T:A	donor_loss	1.0000
6:136151253:TAGGT:T	donor_loss	1.0000
6:136151254:AGGT:A	donor_loss	1.0000
6:136151256:G:GA	donor_loss	1.0000
6:136151256:G:GG	donor_gain	1.0000
6:136151257:T:G	donor_loss	1.0000
6:136154071:CCA:C	acceptor_loss	1.0000
6:136154072:CAGTC:C	acceptor_loss	1.0000
6:136154073:A:AG	acceptor_gain	1.0000
6:136154074:G:A	acceptor_loss	1.0000
6:136154074:G:GC	acceptor_gain	1.0000
6:136154074:GT:G	acceptor_gain	1.0000
6:136154074:GTC:G	acceptor_gain	1.0000
6:136154074:GTCA:G	acceptor_gain	1.0000
6:136154074:GTCAT:G	acceptor_gain	1.0000
6:136154172:AAAGG:A	donor_loss	1.0000
6:136154173:AAGGT:A	donor_loss	1.0000
6:136154174:AGG:A	donor_loss	1.0000
6:136154177:T:G	donor_loss	1.0000
6:136155625:A:AG	acceptor_gain	1.0000
6:136155626:G:GG	acceptor_gain	1.0000
6:136155755:TCAGG:T	donor_loss	1.0000
6:136155756:CAG:C	donor_loss	1.0000

AlphaMissense

3034 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:136154113:C:G	H173D	1.000
6:136155688:A:T	D214V	1.000
6:136181264:G:C	R329T	1.000
6:136181265:A:C	R329S	1.000
6:136181265:A:T	R329S	1.000
6:136181287:T:A	W337R	1.000
6:136181287:T:C	W337R	1.000
6:136149111:T:A	W115R	0.999
6:136149111:T:C	W115R	0.999
6:136149113:G:C	W115C	0.999
6:136149113:G:T	W115C	0.999
6:136154110:T:G	Y172D	0.999
6:136154115:C:A	H173Q	0.999
6:136154115:C:G	H173Q	0.999
6:136154125:C:G	H177D	0.999
6:136154129:C:A	A178E	0.999
6:136154131:G:C	A179P	0.999
6:136154132:C:A	A179D	0.999
6:136154146:G:C	A184P	0.999
6:136155676:C:A	A210E	0.999
6:136155684:C:G	H213D	0.999
6:136155688:A:C	D214A	0.999
6:136155688:A:G	D214G	0.999
6:136155689:T:A	D214E	0.999
6:136155689:T:G	D214E	0.999
6:136155696:C:G	H217D	0.999
6:136155698:C:A	H217Q	0.999
6:136155698:C:G	H217Q	0.999
6:136155702:G:T	G219W	0.999
6:136155703:G:A	G219E	0.999

dbSNP variants (sampled 300 via entrez): RS1000003348 (6:136077396 G>A), RS1000003911 (6:136084698 A>G), RS1000025198 (6:136019105 T>C), RS1000025488 (6:135929861 C>G), RS1000025977 (6:135873456 T>C), RS1000032930 (6:135887748 G>A), RS1000036261 (6:135862963 G>A), RS1000036329 (6:136100949 A>T), RS1000056681 (6:135930166 C>T), RS1000062893 (6:135868962 CAT>C), RS1000092470 (6:136189587 T>A,C), RS1000094573 (6:136053939 T>C), RS1000105226 (6:135881670 G>A,T), RS1000107672 (6:136099279 G>A), RS1000108607 (6:136121707 T>C)

Disease associations

OMIM: gene MIM:604645 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

28 associations (top):

Study	Trait	p-value
GCST000703_4	Phosphorus levels	3.000000e-12
GCST001915_16	Alzheimer’s disease (cognitive decline)	1.000000e-08
GCST002168_6	Intraocular pressure	2.000000e-06
GCST005580_18	Intraocular pressure	2.000000e-14
GCST005580_41	Intraocular pressure	6.000000e-13
GCST005851_6	Delirium	1.000000e-07
GCST005926_2	Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma	6.000000e-07
GCST006065_17	Glaucoma (primary open-angle)	1.000000e-14
GCST006066_3	Glaucoma (primary open-angle)	7.000000e-06
GCST006288_467	Heel bone mineral density	5.000000e-06
GCST006288_561	Heel bone mineral density	3.000000e-11
GCST006394_9	Intraocular pressure	4.000000e-16
GCST006395_46	Glaucoma	8.000000e-08
GCST006412_60	Intraocular pressure	4.000000e-19
GCST006719_2	BRCA1/2-negative high-risk breast cancer	1.000000e-06
GCST006979_397	Heel bone mineral density	1.000000e-16
GCST006979_398	Heel bone mineral density	2.000000e-11
GCST006993_9	Hippocampal volume in Alzheimer’s disease dementia	2.000000e-08
GCST008174_3	Aspartate aminotransferase levels	3.000000e-08
GCST008256_4	Diverticulitis	1.000000e-06
GCST008467_11	Aspartate aminotransferase levels in non-alcoholic fatty liver disease	9.000000e-06
GCST009722_11	Glaucoma (multi-trait analysis)	7.000000e-17
GCST009725_19	Intraocular pressure	2.000000e-16
GCST010083_125	Hemoglobin levels	1.000000e-11
GCST011438_20	Glaucoma (primary open-angle)	4.000000e-09
GCST011439_9	Glaucoma (primary open-angle)	4.000000e-08
GCST011639_4	Cirrhosis (alcohol related)	1.000000e-06
GCST90011770_6	Glaucoma (primary open-angle)	2.000000e-29

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004861	phosphorus measurement
EFO:0004695	intraocular pressure measurement
EFO:0005843	cortisol measurement
EFO:0009175	response to synacthen
EFO:0009270	heel bone mineral density
EFO:0009443	BRCAX breast cancer
EFO:0005035	hippocampal volume
EFO:0004736	aspartate aminotransferase measurement
EFO:0004509	hemoglobin measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2111411 (PROTEIN FAMILY), CHEMBL2363066 (PROTEIN FAMILY), CHEMBL4716 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 72,835 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1520	VARDENAFIL	4	21,078
CHEMBL932	DIPYRIDAMOLE	4	51,743
CHEMBL3770459	LENRISPODUN PHOSPHATE	1	14

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
dipyridamole	Inhibition	6.0	pIC50
SCH51866	Inhibition	5.8	pIC50
BRL50481	Inhibition	4.9	pIC50

Binding affinities (BindingDB)

11 measured of 16 human assays (16 total across all organisms); most potent 11 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
6-(4-amino-2-methoxyphenyl)-3-cyclohexyl-1-methyl-3,5-dihydropyrazolo[4,3-c]pyridin-1-ium-4-one	IC50	1.3 nM	US-8637528: Use of PDE7 inhibitors for the treatment of movement disorders
US8637528, OM056	IC50	5.67 nM	US-8637528: Use of PDE7 inhibitors for the treatment of movement disorders
8-chloro-5-propoxyspiro[1,3-dihydroquinazoline-4,1’-cyclohexane]-2-one	IC50	51.8 nM	US-8637528: Use of PDE7 inhibitors for the treatment of movement disorders
N-[4-(5-cyclohexylimino-4-methyl-1,3,4-thiadiazol-2-yl)phenyl]acetamide	IC50	140 nM	US-8637528: Use of PDE7 inhibitors for the treatment of movement disorders
2-{2-ethoxy-5-[(4-ethylpiperazine-1-)sulfonyl]phenyl}-5-methyl-7-propyl-3H,4H-imidazo[1,5-a][1,2,4]triazin-4-one	IC50	300 nM
CHEMBL3359649	IC50	1110 nM
SILDENAFIL CITRATE	IC50	1500 nM
(6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1,2,1,6]pyrido[3,4-b]indole-1,4-dione	IC50	50000 nM
3-(cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide	IC50	68000 nM
Ariflo	IC50	87000 nM
(E)-{1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethylidene}amino carbamate	IC50	190000 nM

ChEMBL bioactivities

482 potent at pChembl≥5 of 491 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.00	IC50	0.1	nM	CHEMBL5081214
9.90	IC50	0.1259	nM	CHEMBL5080391
9.80	IC50	0.1585	nM	CHEMBL5087564
9.60	IC50	0.2512	nM	CHEMBL5094110
9.50	IC50	0.3162	nM	CHEMBL5086895
9.50	IC50	0.3162	nM	CHEMBL5076558
9.00	IC50	1	nM	CHEMBL5078680
9.00	IC50	1	nM	CHEMBL5088742
9.00	IC50	1	nM	CHEMBL3354181
8.77	IC50	1.7	nM	CHEMBL5180503
8.48	IC50	3.3	nM	CHEMBL3403346
8.32	IC50	4.8	nM	CHEMBL3924897
8.26	IC50	5.5	nM	CHEMBL5625053
8.21	IC50	6.1	nM	CHEMBL5630856
8.10	IC50	8	nM	CHEMBL2019112
8.03	IC50	9.27	nM	CHEMBL3670399
8.00	IC50	10	nM	CHEMBL5879134
8.00	IC50	10	nM	CHEMBL5858692
7.96	IC50	11	nM	CHEMBL2171422
7.89	IC50	13	nM	CHEMBL6170526
7.85	IC50	14	nM	CHEMBL5630984
7.85	IC50	14	nM	CHEMBL183465
7.80	IC50	16	nM	CHEMBL182703
7.77	IC50	17	nM	CHEMBL2019104
7.77	IC50	17	nM	CHEMBL5196667
7.73	IC50	18.8	nM	CHEMBL5890900
7.72	IC50	19	nM	CHEMBL2171423
7.70	IC50	20	nM	CHEMBL5624926
7.64	IC50	23	nM	CHEMBL5625140
7.51	IC50	31	nM	CHEMBL2019021
7.43	IC50	37	nM	CHEMBL3646900
7.41	IC50	39	nM	CHEMBL3646893
7.38	IC50	41.3	nM	CHEMBL4128481
7.37	IC50	43	nM	CHEMBL2171421
7.34	IC50	46	nM	CHEMBL3646899
7.27	IC50	54	nM	CHEMBL6166903
7.26	IC50	55	nM	CHEMBL183965
7.26	IC50	55	nM	CHEMBL5836044
7.26	IC50	55	nM	CHEMBL5814196
7.26	IC50	55	nM	CHEMBL5844793
7.26	IC50	55	nM	CHEMBL5809291
7.26	IC50	55	nM	CHEMBL5854016
7.26	IC50	55	nM	CHEMBL5827612
7.26	IC50	55	nM	CHEMBL5886081
7.26	IC50	55	nM	CHEMBL5899802
7.26	IC50	55	nM	CHEMBL5804823
7.26	IC50	55	nM	CHEMBL5932910
7.26	IC50	55	nM	CHEMBL6053963
7.26	IC50	55	nM	CHEMBL5876453
7.26	IC50	55	nM	CHEMBL5833606

PubChem BioAssay actives

97 with measured affinity, of 236 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]sulfamoyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0001	uM
[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-[[N-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxycarbonyl]anilino]methyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0001	uM
[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]amino]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0002	uM
[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]amino]methyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0003	uM
[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]sulfamoyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0003	uM
[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-[[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]amino]methyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0003	uM
[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[N-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxycarbonyl]anilino]methyl]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0010	uM
[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-[[2-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]-2-oxo-1-phenylethyl]amino]benzoate	1812119: Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay	ic50	0.0010	uM
8-chloro-5-[(2-(111C)methyltetrazol-5-yl)methoxy]spiro[1,3-dihydroquinazoline-4,1’-cyclohexane]-2-one	1924461: Inhibition of PDE7 (unknown origin)	ic50	0.0017	uM
3-ethyl-7-[1-(6-methylpyridine-2-carbonyl)pyrrolidin-3-yl]-2-(propan-2-ylamino)thieno[3,2-d]pyrimidin-4-one	2131356: Inhibition of PDE7 (unknown origin)	ic50	0.0033	uM
2-[3-[(3,4-dimethoxyphenyl)methyl]-2,4-dioxo-1-(thian-4-yl)quinazolin-6-yl]oxyacetonitrile	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.0055	uM
2-[3-[(3,4-dimethoxyphenyl)methyl]-2,4-dioxo-1-(1-oxothian-4-yl)quinazolin-6-yl]oxyacetonitrile	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.0061	uM
6-[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]-3-cyclohexyl-5H-[1,2]thiazolo[5,4-d]pyrimidin-4-one	657348: Displacement of [3H]-cAMP from human recombinant PDE7B	ic50	0.0080	uM
3-[2,2-difluoro-5-(trifluoromethyl)cyclohexyl]-N-[(2,4-dimethoxyphenyl)methyl]-N-[(3,5-dimethoxyphenyl)methyl]triazolo[4,5-d]pyrimidin-7-amine	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.0100	uM
2-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-cyclohexyl-7-methyl-3H-imidazo[4,5-d]pyridazin-4-one	702752: Inhibition of cloned human recombinant PDE7B assessed as [3H]cAMP hydrolysis by radiometric assay	ic50	0.0110	uM
4-[2-(3,4-dimethylphenyl)-5-(4-methylpiperazin-1-yl)-4,5,6,7-tetrahydroindol-1-yl]-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide	2131346: Inhibition of PDE7B (unknown origin) by 3H-cAMP scintillation proximity assay	ic50	0.0140	uM
8-chloro-6-[4-(4-methylpiperazine-1-carbonyl)phenyl]spiro[1,3-dihydroquinazoline-4,1’-cyclohexane]-2-one	2131361: Inhibition of recombinant PDE7 (unknown origin) expressed in Escherichia coli BL21 (DE3) using [3H]cAMP as substrate preincubated for 15 mins followed by compound addition and incubated for 1 hr by liquid scintillation method	ic50	0.0140	uM
8-chloro-6-phenylspiro[1,3-dihydroquinazoline-4,1’-cyclohexane]-2-one	2131361: Inhibition of recombinant PDE7 (unknown origin) expressed in Escherichia coli BL21 (DE3) using [3H]cAMP as substrate preincubated for 15 mins followed by compound addition and incubated for 1 hr by liquid scintillation method	ic50	0.0160	uM
3-cyclohexyl-6-[4-(1,4-diazepan-1-yl)-2-methoxyphenyl]-5H-[1,2]thiazolo[5,4-d]pyrimidin-4-one	657348: Displacement of [3H]-cAMP from human recombinant PDE7B	ic50	0.0170	uM
8-chloro-5-(2-(18F)fluoroethoxy)spiro[1,3-dihydroquinazoline-4,1’-cyclohexane]-2-one	1924461: Inhibition of PDE7 (unknown origin)	ic50	0.0170	uM
5-cyclohexyl-2-[4-(1,4-diazepan-1-yl)-2-methoxyphenyl]-7-methyl-3H-imidazo[4,5-d]pyridazin-4-one	702752: Inhibition of cloned human recombinant PDE7B assessed as [3H]cAMP hydrolysis by radiometric assay	ic50	0.0190	uM
N-cyclopentyl-2-(3,4,5-trimethoxyphenyl)thieno[2,3-d]pyrimidin-4-amine	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.0200	uM
(4aS,8aR)-4-(3-chloro-4-methoxyphenyl)-2-[1-(morpholine-4-carbonyl)piperidin-4-yl]-4a,5,8,8a-tetrahydrophthalazin-1-one	2131346: Inhibition of PDE7B (unknown origin) by 3H-cAMP scintillation proximity assay	ic50	0.0230	uM
6-(4-amino-2-methoxyphenyl)-3-cyclohexyl-5H-[1,2]thiazolo[5,4-d]pyrimidin-4-one	657348: Displacement of [3H]-cAMP from human recombinant PDE7B	ic50	0.0310	uM
5-[[6-(1,3-difluoropropan-2-yloxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxoquinazolin-3-yl]methyl]-2-phenylbenzonitrile	2131355: Inhibition of PDE7 (unknown origin) by fluorescent based assay	ic50	0.0370	uM
4-[6-(1,3-difluoropropan-2-yloxy)-3-[(3,4-dimethoxyphenyl)methyl]-2,4-dioxoquinazolin-1-yl]piperidine-1-carbaldehyde	2131355: Inhibition of PDE7 (unknown origin) by fluorescent based assay	ic50	0.0390	uM
7,8-dimethoxy-N-[(2S)-1-(5-methyl-1H-pyrazol-3-yl)propan-2-yl]quinazolin-4-amine	1495737: Inhibition of full length recombinant human PDE7B using 3’,5’-[3H]cAMP as substrate after 30 mins by scintillation proximity assay	ic50	0.0413	uM
2-(4-amino-2-methoxyphenyl)-5-cyclohexyl-7-methyl-3H-imidazo[4,5-d]pyridazin-4-one	702752: Inhibition of cloned human recombinant PDE7B assessed as [3H]cAMP hydrolysis by radiometric assay	ic50	0.0430	uM
4-[6-(1,3-difluoropropan-2-yloxy)-3-[[3-methoxy-4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]methyl]-2,4-dioxoquinazolin-1-yl]piperidine-1-carbaldehyde	2131355: Inhibition of PDE7 (unknown origin) by fluorescent based assay	ic50	0.0460	uM
8-chloro-5-(2-hydroxyethoxy)spiro[1,3-dihydroquinazoline-4,1’-cyclohexane]-2-one	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.0550	uM
6,7-difluoro-1H-quinazoline-2,4-dithione	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.0740	uM
2-(2,2-dimethylpropylsulfanyl)-3-phenylquinazolin-4-one	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.1000	uM
3-(2,6-difluorophenyl)-8-methyl-2-methylsulfanylquinazolin-4-one	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.1300	uM
8-chlorospiro[1,3-dihydroquinazoline-4,1’-cyclohexane]-2-one	2131361: Inhibition of recombinant PDE7 (unknown origin) expressed in Escherichia coli BL21 (DE3) using [3H]cAMP as substrate preincubated for 15 mins followed by compound addition and incubated for 1 hr by liquid scintillation method	ic50	0.1700	uM
(11R,15S)-5-anilino-8-methyl-4-[(4-pyridin-2-ylphenyl)methyl]-1,3,4,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one	1281082: Inhibition of recombinant full lenght human PDE7B using fluorescent labeled cAMP as substrate after 15 mins by IMAP assay	ki	0.3000	uM
N-(2-pyrazin-2-yl-4,6-dihydrothieno[3,4-c]pyrazol-3-yl)naphthalene-1-carboxamide	1994821: Inhibition of PDE (unknown origin)	ic50	0.3300	uM
(11R,15S)-5-anilino-4-[[4-(6-fluoro-2-pyridinyl)phenyl]methyl]-8-methyl-1,3,4,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one;phosphoric acid	1281082: Inhibition of recombinant full lenght human PDE7B using fluorescent labeled cAMP as substrate after 15 mins by IMAP assay	ki	0.3600	uM
2,3-diphenyl-N-(pyridin-3-ylmethyl)-1,2,4-thiadiazol-5-imine	2131355: Inhibition of PDE7 (unknown origin) by fluorescent based assay	ic50	0.3800	uM
3-(2,6-difluorophenyl)-2-methylsulfanylquinazolin-4-one	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.5100	uM
3-phenyl-1H-quinazoline-2,4-dithione	2131351: Inhibition of full length PDE7 (unknown origin) using FAM-cAMP as substrate by fluorescence based analysis	ic50	0.5500	uM
4-(2-chloro-4-nitrophenyl)sulfanylpyridine	1166730: Inhibition of human recombinant PDE7B assessed as inhibition of hydrolysis of [3H]cAMP after 20 mins by scintillation proximity assay	ic50	0.6000	uM
Dipyridamole	2128853: Inhibition of PDE7 (unknown origin)	ic50	0.6000	uM
N,N,2-trimethyl-5-nitrobenzenesulfonamide	2131346: Inhibition of PDE7B (unknown origin) by 3H-cAMP scintillation proximity assay	ic50	0.6200	uM
2-propan-2-yl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methylsulfanyl]quinazoline	737544: Inhibition of PDE7 catalytic domain (unknown origin) using [3H]-cAMP as substrate after 1 hr by scintillation proximity assay	ic50	0.7700	uM
3-[4-[(2-propan-2-ylquinazolin-4-yl)sulfanylmethyl]phenyl]benzoic acid	737544: Inhibition of PDE7 catalytic domain (unknown origin) using [3H]-cAMP as substrate after 1 hr by scintillation proximity assay	ic50	0.8500	uM
2-propan-2-yl-4-[[4-[3-(2H-tetrazol-5-yl)phenyl]phenyl]methylsulfanyl]quinazoline	737544: Inhibition of PDE7 catalytic domain (unknown origin) using [3H]-cAMP as substrate after 1 hr by scintillation proximity assay	ic50	0.8900	uM
(11R,15S)-5-anilino-8-methyl-4-[(4-phenylphenyl)methyl]-1,3,4,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one	1281082: Inhibition of recombinant full lenght human PDE7B using fluorescent labeled cAMP as substrate after 15 mins by IMAP assay	ki	0.9100	uM
4-[4-[(2-propan-2-ylquinazolin-4-yl)sulfanylmethyl]phenyl]benzoic acid	737544: Inhibition of PDE7 catalytic domain (unknown origin) using [3H]-cAMP as substrate after 1 hr by scintillation proximity assay	ic50	0.9300	uM
[(E)-1-(3-cyclopentyloxy-4-methoxyphenyl)ethylideneamino] carbamate	1797296: Phosphodiesterase (PDE) Inhibition Assay from Article 10.1016/j.str.2004.10.004: “Structural basis for the activity of drugs that inhibit phosphodiesterases.”	ic50	0.9900	uM
1-(6-fluoro-3-pyridinyl)-6-methoxy-3,4-dimethyl-8-pyridin-4-ylimidazo[1,5-a]quinoxaline	1265661: Inhibition of human PDE7B using [3H]cAMP as substrate after 30 mins by scintillation proximity assay	ic50	1.0000	uM

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	3
sodium arsenite	affects expression, decreases expression, increases abundance	2
Cyclic AMP	decreases reaction, increases hydrolysis	2
Arsenic	affects methylation, decreases expression, increases abundance	2
Dipyridamole	decreases reaction, increases hydrolysis	2
Tobacco Smoke Pollution	decreases expression	2
1-Methyl-3-isobutylxanthine	decreases reaction, increases hydrolysis	2
testosterone enanthate	increases hydrolysis, increases metabolic processing	1
methyleugenol	decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
trichostatin A	decreases expression	1
vinpocetine	decreases reaction, increases hydrolysis	1
sulforaphane	decreases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	increases methylation	1
cupric chloride	decreases expression	1
coumarin	decreases phosphorylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
E 4021	decreases reaction, increases hydrolysis	1
SCH 51866	increases hydrolysis, decreases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
2,2’,4,4’,5-brominated diphenyl ether	decreases expression	1
belinostat	increases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1

ChEMBL screening assays

89 unique, capped per target: 83 binding, 4 admet, 1 functional, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1943244	Binding	Inhibition of recombinant human PDE7 using [3H]cAMP as substrate by scintillation proximity assay	The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia. — Bioorg Med Chem Lett
CHEMBL4348842	ADMET	Inhibition of PDE7 (unknown origin)	Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability. — J Med Chem
CHEMBL858855	Functional	Inhibition of PDE7 in HuT78 cells at 100 uM	First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer